Tomiyuki Sugi, Mitsuo Mita, Ryouta Kushi, Homare Hanai, Tomoyuki Uchida, Morihiro Inoue, Masao Hagihara
International journal of clinical pharmacology and therapeutics 2023 NovAt our institution, patients with hematological disease who require Pneumocystis jirovecii pneumonia (PJP) prophylaxis were administered atovaquone at a low dose (750 mg/day). However, there have been few reports on the efficacy of low-dose atovaquone administration, and the purpose of this study is, therefore, to investigate its effectiveness. We investigated the expression of PJP in patients with hematological disease who received atovaquone administration. Atovaquone was administered at a low dose of 750 mg once daily, and the follow-up time was the period of PJP prophylaxis that included atovaquone administration. 85 patients were included in the study. The median age of the study population was 72 years (range: 33 - 97). The duration of atovaquone treatment and follow-up time were 150 days (22 - 1,018) and 258 days (22 - 1,457), respectively. In hematologic diseases, multiple myeloma was high in 31 patients and malignant lymphoma in 28 patients. No patients exhibited PJP during the observation period. In hematological disease patients with relatively low</a> risk of PJP, low-dose atovaquone may prevent the onset of PJP.
Tomiyuki Sugi, Mitsuo Mita, Ryouta Kushi, Homare Hanai, Tomoyuki Uchida, Morihiro Inoue, Masao Hagihara. Prevention of pneumocystis pneumonia in patients with hematological diseases: Efficacy of low-dose atovaquone. International journal of clinical pharmacology and therapeutics. 2023 Nov;61(11):515-519
PMID: 37622674
View Full Text